Cullinan Oncology, Inc. — Q3 2021 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2021; filed November 9, 2021. The filing identifies the registrant as Cullinan Oncology, Inc. (Nasdaq: CGEM); the request metadata uses Cullinan Therapeutics, so confirm the intended issuer and any subsequent name change.
Business context and financial results
The company is an early-stage oncology biopharmaceutical developer with no approved products or product-sale revenue. Its lead clinical program was CLN-081; CLN-049 and CLN-619 had received FDA IND clearance, with trials planned for Q4 2021. Financial amounts below are in millions, except per-share data.
| Metric | Q3 2021 | Nine months 2021 | Comparable 2020 |
|---|---|---|---|
| License revenue | $0 | $18.9 | $0 |
| Research and development expense | $12.7 | $36.9 | $9.9 / $26.6 |
| General and administrative expense | $5.7 | $15.7 | $1.6 / $4.6 |
| Total operating expenses | $18.4 | $52.6 | $11.5 / $31.2 |
| Net loss | $18.3 | $33.3 | $11.3 / $30.4 |
| Net loss attributable to Cullinan common stockholders | $17.4 | $33.1 | $9.9 / $23.5 |
| Loss per share, basic and diluted | $0.40 | $0.76 | $0.50 / $1.21 |
Q3 and nine-month figures are compared with the corresponding 2020 periods. No meaningful operating margin is presented; the company remains loss-making and reported no Q3 revenue.
Financial position, cash flow and changes
- At September 30, 2021, cash and cash equivalents were $88.1 million; short- and long-term investments were $232.9 million and $124.3 million. Combined cash and investments totaled $445.4 million, versus $210.2 million at December 31, 2020.
- Total assets were $453.4 million; current liabilities were $7.9 million and total liabilities $7.9 million. The filing reports no debt.
- Nine-month operating cash use was $28.3 million; investing cash use was $317.9 million, largely reflecting purchases of marketable securities; financing provided $266.1 million, primarily from the IPO. Cash and cash equivalents declined $80.1 million, while much of the proceeds were held in investments.
- The January 2021 IPO generated $264.5 million of net proceeds from 13.685 million shares sold at $21 per share. Shares outstanding were 43.66 million at quarter-end and 43.68 million on November 2, 2021.
- Revenue was a one-time $18.9 million net upfront license fee from Zai Lab for CLN-081 rights in China, Hong Kong, Macau and Taiwan. The agreement also provides for up to $211 million in milestone payments and royalties; no milestones had been achieved.
Year-to-date operating expenses rose $21.4 million from 2020, while net loss increased $2.9 million. Higher research and development spending, public-company costs, and $12.2 million of equity-based compensation contributed to the increase. The 2020 comparison included a $6.4 million noncash CLN-619 in-process R&D charge; the 2021 period included the license revenue. Q3 R&D increased $2.8 million and G&A increased $4.1 million year over year.
Outlook, risks and unusual items
- Management said available cash and investments were expected to fund operations through 2024, based on current plans and assumptions. The financial-statement liquidity note separately says resources should cover at least the next twelve months; investors should note the different stated horizons.
- Management expects operating losses and R&D spending to increase as clinical development advances, including planned CLN-049 and CLN-619 trial starts in Q4 2021. The filing gives no financial guidance beyond the runway estimate.
- CLN-081 was in a Phase 1/2a trial. The company reported 67 enrolled patients, including 36 in the 100 mg twice-daily cohort; at the June ASCO data cutoff, 21 of 42 response-evaluable patients had partial responses, of which 13 were confirmed. The company planned a further clinical update in Q4 2021 and cautioned that interim results may change.
- CLN-617 was selected as a lead candidate and entered IND-enabling studies, as announced in November 2021. Apollo was dissolved in August 2021 after its program was terminated.
- Key risks include clinical failure or safety issues, patient-enrollment delays, reliance on third-party research and manufacturing providers, COVID-19 impacts, competition, intellectual-property risks, and the need for additional capital. Continued losses and dilution or subsidiary-level financing are possible.
- No material litigation was reported. The company said disclosure controls were effective at a reasonable-assurance level and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer’s legal name and relationship to the “Cullinan Therapeutics” name in the request metadata.
- Track CLN-081’s final and updated clinical data, including confirmation of responses, safety, and enrollment progress.
- Verify whether CLN-049 and CLN-619 trials began on the stated timeline and review their clinical and safety updates.
- Assess actual cash burn and runway against management’s through-2024 estimate, including the shorter horizon stated in the liquidity note.
- Review the Zai Lab license terms, revenue-sharing obligations to Taiho, and any milestone or royalty revenue as it is earned.
- Monitor equity-based compensation, potential dilution, and ownership/control changes in the partially owned development subsidiaries.